

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Dupilumab for treating severe chronic rhinosinusitis with nasal polyposis [ID6480]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

During the scoping process, it was noted that there are differences in the quality of surgery across centres in the UK, which increases inequality in access to optimal healthcare. Additionally, follow-up post-operative pathway for people also varies with geographical location, which means underserved people become more reliant on already overstretched local primary care services. The introduction of the biologic in the NHS as an alternative option to current standard care for patients failing after surgery will help reduce the significant timelines for patients waiting for revision surgery.

It was also noted that patients with multiple co-morbidities may be less likely to be able to safely take steroids in any formulation or undergo surgery and would therefore not be covered under the population description as previously treated severe chronic rhinosinusitis with nasal polyps.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The committee can only appraise the technology within its marketing authorisation. The committee will consider all potential equality issues during the appraisal process.

3. Has any change to the draft scope been agreed to highlight potential equality issues?
No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?
No.

Approved by Associate Director (name): ...Richard Diaz.....

Date: 19 Nov 2024